Profil
Dr. Emil T.
Kuriakose, MD, is a Chief Medical Officer-Oncology at Terns Pharmaceuticals, Inc. Dr. Kuriakose was previously employed as a Chief Medical Officer by Calithera Biosciences, Inc. and a Medical Director by Novartis Oncology, Inc. He received his undergraduate degree from New York University and a doctorate degree from Stony Brook University School of Medicine.
Postes actifs de Emil Kuriakose
| Sociétés | Poste | Début |
|---|---|---|
| TERNS PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 01/05/2023 |
Anciens postes connus de Emil Kuriakose
| Sociétés | Poste | Fin |
|---|---|---|
Novartis Oncology, Inc.
Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Directeur Technique/Scientifique/R&D | 01/01/2016 |
| CALITHERA BIOSCIENCES, INC. | Directeur Technique/Scientifique/R&D | - |
Formation de Emil Kuriakose
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Novartis Oncology, Inc.
Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
New York University
New York University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Calithera Biosciences, Inc.
Calithera Biosciences, Inc. BiotechnologyHealth Technology Develops novel therapeutics to control cancer and other diseases | Health Technology |
Stony Brook University School of Medicine
Stony Brook University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops small-molecule product candidates to address serious diseases including oncology and obesity | Health Technology |
















